Synopsis:
Treatment of rheumatoid arthritis has dramatically changed by the appearance of molecular target drugs, and the treatment option with JAK inhibitors had a large impact.
In this symposium, we will explore the clinical efficacy and safety information of filgotinib in the treatment of rheumatoid arthritis, including prevention of structural joint damage, based on the results of pivotal clinical studies. In addition, we will provide a comprehensive review of requiring particular attention when using JAK inhibitors and will discuss the role of filgotinib in the treatment of rheumatoid arthritis.
Agenda:
|
|
Chairperson: Prof. Akio Morinobu
|
|
TBA mins |
The Role of Filgotinib in The Treatment of Rheumatoid Arthritis
Prof Motomu Hashimoto |
|
TBA mins |
Closing Remarks: Q&A and Discussion
All |
